However, there are few diagnostic tests available in the market which are the only saving grace for the global mitochondrial myopathy diagnosis and treatment market at present.
However, the unavailability of treatment for rare genetic diseases, and lack of awareness about the diagnosis of these diseases are major factors restraining the growth of the market.
are major players in the market.Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/3684Key developmentsStrategic approaches adopted help the major players to sustain their growth in the market and develop their business in various geographical areas across the globe.
Agreements and collaborations, mergers and acquisitions, and new product launches are various strategies followed by the key players.Centogene AGApril, 2017: The Centogene AG extended its genetic testing portfolio by adding numerous single gene tests and Next Generation Sequencing (NGS) panels to its portfolio.September, 2016: The Centogene AG announced the release of its genomic database CentoMD 3.1 which consist of genetic data and clinical information from more than 100,000 individuals worldwide.
The database consists of nearly 3 million unique variants 57% of which are unpublished.NeuroVive Pharmaceutical ABMay, 2017: The NeuroVive Pharmaceutical AB entered into a licensing agreement with Korean pharmaceutical company Yungjin Pharm for the study of its substance KL1333 for genetic mitochondrial diseases.January, 2017: NeuroVive Pharmaceutical AB signed a preclinical cooperation agreement with Children’s Hospital of Philadelphia (CHOP) for the study and development of the treatment options for genetic mitochondrial diseases.January, 2017: The NeuroVive Pharmaceutical AB announced a cooperation agreement with Karolinska Institutet.
The main focus in this partnership is to study NeuroVive’s cyclophilic inhibitor NV556 and its effects in experimental models of mitochondrial myopathy.Browse Full Report @ https://www.marketresearchfuture.com/reports/mitochondrial-myopathies-market-3684Khondrion BVSeptember, 2016: Khondrion BV received Euro 1 million worth grant from EFRO of European union for the development of treatment with substance KH176 for the children with mitochondrial diseases.December, 2015: Khondrion BV announced the completion of the Phase I clinical trial with its lead compound KH176.